RxDoctor Payments Data

Masood Ahmad, MD

Pulmonary Disease · Lancaster, PANPI 1114128485

Payments from drug & device makers

$792in general payments, 2019–2025

Across 20 payments — averaging $39.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$159
  • Harmony Biosciences LLC$133
  • GSK$125
  • AstraZeneca$123
  • Boehringer Ingelheim$117
  • ANI Pharmaceuticals, Inc.$61
  • plus $74 from 3 others

What the payments were for

  • Food & beverage$65683%
  • Education$13617%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$792 in reported general payments places this provider in the 40th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$76,302
Medicare patients
300
Services billed
755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$55,748
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr66$34,081
Breo ElliptaFluticasone/Vilanterol76$32,356
Incruse ElliptaUmeclidinium Bromide43$16,181
Spiriva HandihalerTiotropium Bromide20$11,736
Spiriva RespimatTiotropium Bromide20$10,628
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate48$7,528
Roflumilast39$5,789
SymbicortBudesonide/Formoterol Fumarate16$3,697
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$3,218
Albuterol Sulfate HfaAlbuterol Sulfate76$1,806
Montelukast Sodium83$937
Fluticasone Propionate48$581
Azelastine Hcl13$327
Prednisone21$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$125$138,366266 claims
Boehringer IngelheimSpiriva Respimat$117$10,62820 claims
AstraZenecaSymbicort$123$3,69716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →